ClinicalTrials.gg
CompletedNCT04030195Updated Jan 31, 2023Results posted

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

A Phase 1/2 interventional study of PBCAR20A and Fludarabine in Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse and Non-Hodgkin's Lymphoma Refractory, sponsored by Precision BioSciences, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-31.

Sponsored by Precision BioSciences, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 94 studies testing fludarabine in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, none of them phase 3. fludarabine · Lymphoma, Non-Hodgkin.

Enrollment
69th of 94
18 · median 37
Started
2020
with 2 others
Phase 1/2
12 of 94
1 open now
Registered
87th of 94
by date

Among the 94 studies testing fludarabine in Lymphoma, Non-Hodgkin, this one is the 69th largest by enrollment, is one of 3 that started in 2020, is one of 12 in phase 1/2, and was the 87th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

5 of the 94 studies testing fludarabine in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About fludarabine

fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing fludarabine in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR20A in adult subjects with r/r B-cell NHL or r/r CLL/SLL.

Read the detailed description

This is a multicenter, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate safety, tolerability, clinical activity, and find an appropriate dose to optimize safety and efficacy of PBCAR20A in subjects with relapsed/refractory (r/r) CD20+ Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Before initiating PBCAR20A, therapy, subjects will be administered lymphodepletion chemotherapy composed of fludarabine and cyclophosphamide. At Day 0 of the Treatment Period, subjects will receive a single intravenous (IV) infusion of PBCAR20A. All subjects are monitored during the treatment period through Day 28. All subjects who receive a dose of PBCAR20A will be followed in a separate long-term follow-up (LTFU) study for 15 years after exiting this study.

03

Conditions studied

  • Non-Hodgkin's Lymphoma, Relapsed
  • Chronic Lymphoid Leukemia in Relapse
  • Non-Hodgkin's Lymphoma Refractory
  • Chronic Lymphocytic Leukemia
  • Lymphoma, Non-Hodgkin
  • Leukemia, Lymphocytic, Chronic
  • B-cell Chronic Lymphocytic Leukemia
  • B-cell Non Hodgkin Lymphoma
  • Small Lymphocytic Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

Criteria for NHL:

  • r/r CD20+ B-cell NHL that is confirmed by archived tumor tissue from the last relapse and corresponding pathology report.
  • Measurable or detectable disease according to the Lugano classification.
  • Primary disease or r/r disease after a response to 2 prior regimens.

Criteria for CLL/SLL:

  • Diagnosis of CD20+ CLL with indication for treatment based on the iwCLL guidelines and clinically or SLL with measurable disease that is biopsy-proven SLL.
  • Previously failed/tolerant to at least 2 prior lines of systemic targeted therapy of known benefit.

Criteria for both NHL and CLL/SLL:

  • Study participant has an (ECOG) Performance Status score of 0 or 1.
  • Study participant has adequate bone marrow, renal, hepatic, pulmonary, and cardiac function.

Key Exclusion Criteria:

Criteria for NHL:

  • Requirement for urgent therapy due to mass effects such as bowel obstruction, spinal cord, or blood vessel compression.
  • Active central nervous system (CNS) disease. A negative computed tomography (CT)/magnetic resonance imaging (MRI) is required at Screening if the study participant has a history of CNS lymphoma.

Criteria for NHL and CLL/SLL:

  • Active CNS disease. A negative lumbar puncture is required at Screening if the study participant has a history of CNS disease.
  • Previous , besides the malignancies of inclusion (B-cell NHL or CLL/SLL), that in the investigator's opinion, has a high risk of relapse in the next 2 years.
  • Active uncontrolled fungal, bacterial, viral, protozoal, or other infection.
  • Any form of primary immunodeficiency.
  • History of (HIV) infection.
  • Active or C.
  • Uncontrolled cardiovascular disease.
  • Hypertension crisis or hypertensive encephalopathy within 3 months prior to Screening.
  • Presence of a CNS disorder that renders ineligible for treatment.
  • History of a genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman Diamond syndrome, or any other known bone marrow failure syndrome.
  • Received within 45 days of Screening if the study participant has met the rest of the count requirements.
  • Must not have received systemic therapy for at least 7 days prior to initiating lymphodepletion chemotherapy.
  • Received a within 4 weeks before Screening.
  • Radiotherapy within 4 weeks determined on a case-by-case basis.
  • Presence of a pleural/peritoneal/pericardial catheter.
  • Current use of any anticoagulant or antiplatelet therapy.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Dose Level 1 of PBCAR20A CAR T cells

    1 x 10\^6 chimeric antigen receptor (CAR) T cells per kg body weight. In this study, PBCAR20A, allogeneic anti-cluster of differentiation (CD20) CAR T Cells, is used to treat patients with relapsed or refractory (r/r) CD20+ Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Route of Administration: Intravenous infusion (IV) Lymphodepletion Conditioning: Lymphodepletion will be conducted several days prior to PBCAR20A infusion. A combination of fludarabine and cyclophosphamide will be used for lymphodepletion.

    Genetic: PBCAR20A · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Dose Level 2 of PBCAR20A CAR T cells

    240 x 10\^6 CAR T cells (flat dose)

    Genetic: PBCAR20A · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Dose Level 3 of PBCAR20A CAR T cells

    480 x 10\^6 CAR T cells (flat dose)

    Genetic: PBCAR20A · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

  • GeneticPBCAR20A

    Single dose of Allogeneic Anti-CD20 CAR T cells will be infused, and a classic "3+3" dose escalation will be applied.

    Also known as: Allogeneic Anti-CD20 CAR T cells

  • Fludarabine is used for lymphodepletion (30 mg/m\^2/day, Days -5 to -3).

  • Cyclophosphamide is used for lymphodepletion (500 mg/m\^2/day, Days -5 to -3).

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    The maximum tolerated dose (MTD) is the dose level at which fewer than 33% of patients experience a dose limiting toxicity (DLT) using a 3+3 strategy.

    Time frame: Day 1 to Day 28

  2. Number of Participants With Dose-Limiting Toxicities

    Dose-limiting toxicities (DLT) are certain Grade 3 and Grade 4 toxic reactions as defined by the protocol and CTCAE v5.0.

    Time frame: 1 year

Secondary outcomes

  1. Objective Response Rate

    Objective response rate (ORR) is a measure of clinical activity as response in NHL by the revised Lugano Classification (Cheson et al, 2016) or a response in CLL/SLL by the International Workshop on Chronic Lymphocytic Leukemia 2018 guidelines.

    Time frame: 1 year

  2. Progression-free Survival (PFS)

    Progression-free survival is defined as the duration (days) from Day 0 to disease progression or death.

    Time frame: 1 year

07

Results

Posted Jan 31, 2023

Participant flow

Participant flow — Overall Study
MilestoneDose Level 1 of PBCAR20A CAR T CellsDose Level 2 of PBCAR20A CAR T CellsDose Level 3 of PBCAR20A CAR T Cells
Started837
Participants in demographic population836
Participants in safety population836
Participants re-treated001
Participants in efficacy population837
Completed637
Not completed200
Withdrew: Withdrawal by subject200

Outcome measures

PrimaryMaximum Tolerated Dose (MTD)

The maximum tolerated dose (MTD) is the dose level at which fewer than 33% of patients experience a dose limiting toxicity (DLT) using a 3+3 strategy.

Time frame:
Day 1 to Day 28
Reported as:
Number · 10^6 CAR T cells
Maximum Tolerated Dose (MTD)
10^6 CAR T cellsPBCAR20A CAR T Cells
Maximum Tolerated Dose (MTD)NA
PrimaryNumber of Participants With Dose-Limiting Toxicities

Dose-limiting toxicities (DLT) are certain Grade 3 and Grade 4 toxic reactions as defined by the protocol and CTCAE v5.0.

Time frame:
1 year
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities
ParticipantsDose Level 1 of PBCAR20A CAR T CellsDose Level 2 of PBCAR20A CAR T CellsDose Level 3 of PBCAR20A CAR T Cells
Number of Participants With Dose-Limiting Toxicities100
SecondaryObjective Response Rate

Objective response rate (ORR) is a measure of clinical activity as response in NHL by the revised Lugano Classification (Cheson et al, 2016) or a response in CLL/SLL by the International Workshop on Chronic Lymphocytic Leukemia 2018 guidelines.

Time frame:
1 year
Reported as:
Count of participants · Participants
Objective Response Rate
ParticipantsDose Level 1 of PBCAR20A CAR T CellsDose Level 2 of PBCAR20A CAR T CellsDose Level 3 of PBCAR20A CAR T Cells
Responders213
Complete Response100
Partial Response113
Non-responders624
SecondaryProgression-free Survival (PFS)

Progression-free survival is defined as the duration (days) from Day 0 to disease progression or death.

Time frame:
1 year
Reported as:
Median · Days
Progression-free Survival (PFS)
DaysDose Level 1 of PBCAR20A CAR T CellsDose Level 2 of PBCAR20A CAR T CellsDose Level 3 of PBCAR20A CAR T Cells
Progression-free Survival (PFS)29.5 (15.0 to 365.0)29.0 (29.0 to 94.0)29.0 (12.0 to 66.0)

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Level 1 of PBCAR20A CAR T Cells1/8 (12.5%)3/8 (37.5%)8/8 (100%)
Dose Level 2 of PBCAR20A CAR T Cells0/3 (0%)0/3 (0%)3/3 (100%)
Dose Level 3 of PBCAR20A CAR T Cells0/6 (0%)1/6 (16.7%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventDose Level 1 of PBCAR20A CAR T CellsDose Level 2 of PBCAR20A CAR T CellsDose Level 3 of PBCAR20A CAR T Cells
Atrial fibrillationCardiac disorders0/80/31/6
Abdominal painGastrointestinal disorders1/80/30/6
PneumoniaInfections and infestations1/80/30/6
SepsisInfections and infestations1/80/30/6
Transaminases increasedInvestigations1/80/30/6
CAR T cell-related encephalopathy syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/80/30/6
Most frequent other events
Showing 10 of 92
Most frequent other events
EventDose Level 1 of PBCAR20A CAR T CellsDose Level 2 of PBCAR20A CAR T CellsDose Level 3 of PBCAR20A CAR T Cells
AnaemiaBlood and lymphatic system disorders6/81/33/6
Neutrophil count decreasedInvestigations6/82/34/6
ConstipationGastrointestinal disorders1/82/32/6
NauseaGastrointestinal disorders3/82/32/6
FatigueGeneral disorders4/82/31/6
Oedema peripheralGeneral disorders3/81/34/6
PyrexiaGeneral disorders4/82/33/6
Muscular weaknessMusculoskeletal and connective tissue disorders1/82/30/6
HeadacheNervous system disorders1/82/32/6
Cytokine release syndromeImmune system disorders1/81/33/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Dose Level 1 of PBCAR20A CAR T CellsDose Level 2 of PBCAR20A CAR T CellsDose Level 3 of PBCAR20A CAR T CellsTotal
Mean58.25 ± 17.0747.00 ± 19.0858.17 ± 13.7056.24 ± 15.85
Sex: Female, Male
Sex: Female, Male(Participants)Dose Level 1 of PBCAR20A CAR T CellsDose Level 2 of PBCAR20A CAR T CellsDose Level 3 of PBCAR20A CAR T CellsTotal
Female2013
Male63514
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose Level 1 of PBCAR20A CAR T CellsDose Level 2 of PBCAR20A CAR T CellsDose Level 3 of PBCAR20A CAR T CellsTotal
Hispanic or Latino1203
Not Hispanic or Latino71614
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Level 1 of PBCAR20A CAR T CellsDose Level 2 of PBCAR20A CAR T CellsDose Level 3 of PBCAR20A CAR T CellsTotal
American Indian or Alaska Native0000
Asian1012
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White72514
More than one race0000
Unknown or Not Reported0101
Region of Enrollment
Region of Enrollment(participants)Dose Level 1 of PBCAR20A CAR T CellsDose Level 2 of PBCAR20A CAR T CellsDose Level 3 of PBCAR20A CAR T CellsTotal
United States83617
08

Study locations

5 sites
  • City of Hope
    Duarte, California 91010, United States
  • Stanford University
    Stanford, California 94305, United States
  • Columbia University
    New York, New York 10032, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Jun 2021, 15 months.

Results were first posted in Jan 2023, 1 year 7 months after primary completion.

Of 69 industry-sponsored phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 103. This study's 15 months is below that.

Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2019
First posted
Jul 23, 2019
StartActual
Mar 24, 2020
Primary completionActual
Jun 24, 2021
CompletionActual
Jun 24, 2021
Results first posted
Jan 31, 2023
Last update
Jan 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04030195
Lead sponsor
Precision BioSciences, Inc.
Responsible party
Sponsor
First posted
Jul 23, 2019
Start date
Mar 24, 2020
Primary completion
Jun 24, 2021
Completion
Jun 24, 2021
Results posted
Jan 31, 2023
Last update
Jan 31, 2023

Study contacts

Alan List, MD
study chair · Precision BioSciences, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fludarabine · Cyclophosphamide

Start the discussion